Evommune (EVMN) Current Deferred Revenue (2024)
Evommune (EVMN) reported Current Deferred Revenue of $3.0 million for Q4 2024.
Evommune (EVMN) has 1 years of Current Deferred Revenue data on file, last reported at $3.0 million in Q4 2024.
- Quarterly Current Deferred Revenue changed N/A year-over-year to $3.0 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $3.0 million (changed N/A YoY) and the FY2024 annual result came in at $3.0 million, changed N/A from the prior year.
- Current Deferred Revenue held at $3.0 million in Q4 2024 per EVMN's latest filing.
- Across five years, Current Deferred Revenue topped out at $3.0 million in Q4 2024 and bottomed at $3.0 million in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Evommune | 782.16 Mn | 570.69 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 3.00 Mn |